Seborrheic dermatitis is a chronic relapsing skin disorder that presents with erythema, scaling, and pruritus. It is estimated that between 3% and 5% of the population worldwide are affected by seborrheic dermatitis.1 Recent studies have shown the efficacy of pimecrolimus in treating facial seborrheic dermatitis.2- 5 The purpose of this study was to compare the safety and efficacy of topical pimecrolimus with hydrocortisone acetate in the treatment of patients with facial seborrheic dermatitis.
Firooz A, Solhpour A, Gorouhi F, Daneshpazhooh M, Balighi K, Farsinejad K, Rashighi-Firoozabadi M, Dowlati Y. Pimecrolimus Cream, 1%, vs Hydrocortisone Acetate Cream, 1%, in the Treatment of Facial Seborrheic Dermatitis: A Randomized, Investigator-Blind, Clinical Trial. Arch Dermatol. 2006;142(8):1065–1086. doi:10.1001/archderm.142.8.1066
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.